In silico screening and identification of lead molecules from Garcinia gummi-gutta with multitarget activity against SARS-CoV-2

Keerthi J. Sugathan Sivanandan Sreekumar Biju Charuvila Kamalan   

Open Access   

Published:  May 09, 2024

DOI: 10.7324/JAPS.2024.150413

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has affected the human population, resulting in multiple waves of pandemics around the world. One of the main threats is hyper-evolved viral variants with high transmissibility and virulence, and the best solution is the application of multitargeted drugs of plant origin. In this perspective, the anti-SARS-CoV-2 activity of Garcinia gummi-gutta was evaluated through an in silico approach. A total of 97 phytochemicals from G. gummi-gutta were tested against three therapeutic targets of SARS-CoV-2, namely spike protein, main protease (Mpro), RNA-dependent RNA polymerase, and two human host targets such as angiotensin-converting enzyme-2 and nuclear factor-κB through molecular docking. Out of 97 phytochemicals screened, 18 of them showed significant binding free energy with all the five selected targets. The compound amentoflavone was chosen as the best lead molecule based on binding energy, molecular interactions, and absorption distribution metabolism and excretion profile. The interaction of amentoflavone with Mpro was further verified using molecular dynamic simulation. The overall results revealed that the compound amentoflavone can be recommended as the best lead compound with multitargeting potential against SARS-CoV-2, and can be recommended for further experimental studies leading to drug discovery.

Keyword:     SARS-CoV-2 Garcinia gummi-gutta docking molecular dynamic simulation phytochemicals


Sugathan KJ, Sreekumar S, Kamalan BC. In silico screening and identification of lead molecules from Garcinia gummi-gutta with multitarget activity against SARS-CoV-2. J Appl Pharm Sci. 2024. Online First.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text


1. [Internet]. WHO COVID-19 dashboard. Geneva, Switzerland: World Health Organization; 2020 [cited 2023 Sep 19]. Available from:

2. Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, Cuesta-Geijo MÁ, et al. COVID-19: drug targets and potential treatments. J Med Chem. 2020;63(21):12359-86.

3. Janik E, Niemcewicz M, Podogrocki M, Saluk-Bijak J, Bijak M. Existing drugs considered as promising in COVID-19 therapy. Int J Mol Sci. 2021;22(11):5434.

4. Naidoo D, Roy A, Kar P, Mutanda T, Anandraj A. Cyanobacterial metabolites as promising drug lead against the Mpro and PLpro of SARS-CoV-2: an in-silico analysis. J Biomol Struct Dyn. 2021;39(16):6218-30.

5. Jiang Y, Yin W, Xu HE. RNA-dependent RNA polymerase: structure, mechanism, and drug discovery for COVID-19. Biochem Biophys Res Commun. 2021;538:47-53.

6. Singh S, Sk MF, Sonawane A, Kar P, Sadhukhan S. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis. J Biomol Struct Dyn. 2021;39(16):6249-64.

7. Keerthi Sugathan J, Sreekumar S, Biju CK. Identification of lead molecules against multi-target of SARS-CoV-2 from Carica papaya L. through in-silico method. Int J Pharm Sci Drug Res. 2023;15(2):124-31.

8. Rodriguez-Garcia A, Hosseini S, Martinez-Chapa SO, Cordell GA. Multi-target activities of selected alkaloids and terpenoids. Mini Org Chem. 2017;14(4):272-9.

9. Kabir A, Muth A. Polypharmacology: the science of multi-targeting molecules. Pharmacol Res. 2022;176:106055.

10. Anilkumar AT, Manoharan S, Balasubramanian S, Perumal E. Garcinia gummi-gutta: phytochemicals and pharmacological applications. BioFactors. 2023;49(3):584-99.

11. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-91.

12. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx: methods. Mol Biol. 2015;1263:243-50.

13. Trott O, Olson AJ, AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-61.

14. Schrödinger L, DeLano W. PyMOL [Internet]; 2020. Available from:

15. [Internet]. San Diego, CA: BIOVIA, Dassault Systèmes; 2020 [cited 2023 Sep 19]. Available from:

16. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci rep. 2017;7(1):42717.

17. Pires DEV, Blundell TL, Ascher DB. pkCSM predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58:4066-72.

18. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACR2 receptor. Nature. 2020;581:215-20.

19. Choubey A, Dehury B, Kumar S, Medhi B, Mondal P. Naltrexone a potential therapeutic candidate for COVID-19. J Biomol Struct Dyn. 2022;40(3):963-70.

20. Sarah H, Kummetha VIR, Tiwari VSK, Huante MB, Clark AE, Wang S et al. Discovery and mechanism of SARS-CoV-2 main protease inhibitors. J Med Chem. 2022;65:2866-79.

21. Hu Q, Xiong Y, Zhu HH, Zhang YN, Zhang YW, Huang P, et al. The SARS-CoV-2 main protease (Mpro): structure, function, and emerging therapies for COVID-19. MedComm. 2022;3(e151):1-27.

22. Aftab SO, Ghouri MZ, Masood MU, Haider Z, Khan Z, Ahmad A, et al. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med. 2020;18:275.

23. Su CM, Wang L, Yoo D. Activation of NF-kB and induction of proinflammatory cytokine expressions mediated by ORF7 a protein of SARS-CoV-2. Sci Rep. 2021;11:1364.

24. Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O. NF-kB pathway as a potential target for treatment of critical stage COVID-19 patients. Front Immunol. 2020;11:598444.

25. Choudhary S, Singh PK, Verma H, Singh H, Silakari O. Success stories of natural product-based hybrid molecules for multi-factorial diseases. Eur J Med Chem. 2018;151:62-97.

26. Keerthi Sugathan J, Sreekumar S, Biju CK. In silico validation of clove as a potential nutraceutical against SARS-CoV-2. Int J Pharm Sci Res. 2022;13(11):4544-53.

27. Deepa V, Sreekumar S, Biju CK. In-silico validation of anti-russell’s viper venom activity in Phyllanthus emblica L. and Tamarindus indica L. Int J Pharm Sci Drug Res. 2018;10(4):217-26.

28. Veeresham C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res. 2012;3(4):200-1.

29. Shityakov S, Förster C. In silico predictive model to determine vector-mediated transport properties for the blood-brain barrier choline transporter. Adv Appl Bioinforma Chem. 2014;2:23-36.

30. Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron. 2018;99(6):1129-43.

31. Ramírez D, Caballero J. Is it reliable to take the molecular docking top-scoring position as the best solution without considering available structural data? Molecules. 2018;23(5):1038.

32. Wrobel AG. Mechanism and evolution of human ACE2 binding by SARS-CoV-2 spike. Curr Opin Struct Biol. 2023;81:102619.

33. Pang X, Xu W, Liu Y, Li H, Chen L. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022. Eur J Med Chem. 2023;22:115491.

34. Rushworth CA, Guy JL, Turner AJ. Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. FEBS J. 2008;275(23):6033-42.

35. Rocha RE, Chaves EJ, Fischer PH, Costa LS, Grillo IB, Da Cruz LE, et al. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers. J Biomol Struct Dyn. 2002;40(19):9214-34.

36. Yu S, Yan H, Zhang L, Shan M, Chen P, Ding A, et al. A review on the phytochemistry, pharmacology, and pharmacokinetics of amentoflavone, a naturally-occurring biflavonoid. Molecules. 2017;22(2):299.

37. Ma SC, But PP, Ooi VE, He YH, Lee SH, Lee SF, et al. Antiviral amentoflavone from Selaginella sinensis. Biol Pharm Bull. 2001;24:311-2.

38. Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, et al. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod. 1997;60:884-8.

39. Wilsky S, Sobotta K, Wiesener N, Pilas J, Althof N, Munder T, et al. Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication. Arch Virol. 2012;157:259-69.

40. Coulerie P, Nour M, Maciuk A, Eydoux C, Guillemot JC, Lebouvier N, et al. Structure-activity relationship study of biflavonoids on the dengue virus polymerase DENV-NS5 RdRp. Planta Med. 2013;79:1313-8.

41. Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH. Inhibitory effects of amentoflavone and orobol on daclatasvir-induced resistance-associated variants of hepatitis C virus. Am J Chin Med. 2018;46:835-52.

42. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766-88.

Article Metrics
71 Views 16 Downloads 87 Total



Related Search

By author names